K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Journal of Surgical Oncology

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejso.2010.05.014PMID 20542658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer.

  2009cited by this paper
• Low-Level Expression of Smad7 Correlates with Lymph Node Metastasis and Poor Prognosis in Patients with Pancreatic Cancer

  2009cited by this paper
• Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.

  2009cited by this paper
• Results of a Phase I Trial of 12 Patients With Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-ras as a Potential Biomarker of Response to Therapy

  2009cited by this paper
• Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9

  2009cited by this paper
• CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy.

  2008cited by this paper
• Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

  2008cited by this paper
• Tobacco and the risk of pancreatic cancer: a review and meta-analysis

  2008cited by this paper
• K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer Patients: In Relation to Cigarette Smoking

  2007cited by this paper
• Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.

  2007cited by this paper
• Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer.

  2006cited by this paper
• Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation

  2006cited by this paper
• Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

  2004cited by this paper
• Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA.

  2004cited by this paper
• Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients

  2003cited by this paper
• Prognostic factors in the palliation of pancreatic cancer.

  2003cited by this paper
• Prognostic Implications of Routine, Immunohistochemical, and Molecular Staging in Resectable Pancreatic Adenocarcinoma

  2002cited by this paper
• Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA

  2002cited by this paper
• Epidemiological Trends in Pancreatic Neoplasias

  2001cited by this paper
• Physical activity, obesity, height, and the risk of pancreatic cancer.

  2001cited by this paper
• K‐ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4A, p21WAF‐1, cyclin D1, erbB‐2 and erbB‐3 in resected pancreatic ductal adenocarcinoma

  2000cited by this paper
• K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.

  2000cited by this paper
• K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

  1999cited by this paper
• A prospective study of K-ras mutations in the plasma of pancreatic cancer patients.

  1998cited by this paper
• Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.

  1998cited by this paper
• Pancreatic cancer in europe: Ki‐ras gene mutation pattern shows geographical differences

  1994cited by this paper
• Comparative analysis of mutations in the p53 and K‐ras genes in pancreatic cancer

  1994cited by this paper
• K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

  1994cited by this paper
• K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

  1993cited by this paper
• Free DNA in the serum of cancer patients and the effect of therapy.

  1977cited by this paper

• Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.

  2026cites this paper
• PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation

  2025cites this paper
• Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis

  2025cites this paper
• Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study

  2024influential citation
• Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma

  2024cites this paper
• ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.

  2024cites this paper
• The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

  2024cites this paper
• Evaluation of the diagnostic and prognostic clinical values of circulating tumor DNA and cell-free DNA in pancreatic malignancies: a comprehensive meta-analysis

  2024cites this paper
• Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer

  2023cites this paper
• Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.

  2023cites this paper
• Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging

  2023cites this paper
• State of the Art: ctDNA in Upper Gastrointestinal Malignancies

  2023cites this paper
• Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma

  2022cites this paper
• „Liquid biopsy“ in der gastrointestinalen Onkologie: Hype oder bald Realität?

  2022cites this paper
• Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies

  2022cites this paper
• Is Cell-Free DNA Testing in Pancreatic Ductal Adenocarcinoma Ready for Prime Time?

  2022influential citation
• Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer

  2021cites this paper
• An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression

  2021cites this paper
• Ultra-low Input Circulating Tumor DNA Detection by MED-Amp in Early-Stage Pancreatic Cancer

  2021cites this paper
• Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer

  2021cites this paper
• Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients

  2021cites this paper
• Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing

  2021cites this paper
• Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives

  2021cites this paper
• CMAR_A_308029 6249..6261

  2021cites this paper
• Prognostic Value of KRAS Mutations in the Peripheral Blood of Patients with Pancreatic Cancer: a Systematic Review and Meta-analysis

  2021cites this paper
• Implementing biological markers as a tool to guide clinical care of patients with pancreatic cancer

  2020cites this paper
• Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer

  2020cites this paper
• Meta-analysis of the studies dedicated to the predictive significance of circulating tumor DNA in pancreatic cancer

  2020cites this paper
• Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis

  2020cites this paper
• Circulating Tumor DNA as a Novel Biomarker for Pancreatic Cancer

  2020cites this paper
• Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers

  2020cites this paper
• Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis

  2020cites this paper
• Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.

  2020cites this paper
• Kras-Diagnosing the Little-Known Cancers Oncogene through Liquid Biopsy: Review

  2020cites this paper
• Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas

  2020cites this paper
• A Nomogram for Individual Prediction of Poor Prognosis After Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma

  2020cites this paper
• Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

  2020cites this paper
• Biomarkers of Pancreatic Cancer

  2019cites this paper
• Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA

  2019influential citation
• Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review.

  2019cites this paper
• Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Kirsten Rat Sarcoma Viral Oncogene Homologue（KRAS） mutations in the occurrence and treatment of pancreatic cancer.

  2019cites this paper
• Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma

  2019cites this paper
• Inflammation and pancreatic cancer: An updated review

  2019cites this paper
• Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma

  2019cites this paper
• Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?

  2019cites this paper
• Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma.

  2019cites this paper
• The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA

  2019cites this paper
• Management of pancreatic ductal adenocarcinoma (PDAC): Progress in the past decade and challenges for the future

  2019cites this paper
• Tumour biomarkers—Tracing the molecular function and clinical implication

  2019cites this paper
• Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer

  2019cites this paper
• Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer

  2019cites this paper
• The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

  2019cites this paper
• Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis

  2019cites this paper
• Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.

  2018cites this paper
• Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer

  2018cites this paper
• GENETIC EVOLUTION AND PROGNOSTIC DETERMINANTS OF PANCREATIC CANCER ON LONGITUDINAL LIQUID BIOPSIES

  2018cites this paper
• A novel nanoprobe-based assay for detecting K- ras mutations in plasma and stool samples from patients with pancreatic cancer: value in diagnosis and prognosis evaluation

  2018cites this paper
• Liquid biopsies for management of pancreatic cancer

  2018cites this paper
• Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool?

  2018cites this paper
• Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective

  2018cites this paper
• The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer

  2018cites this paper
• Kras, epidermal growth factor receptor, and p53, but not Nras or Braf, biomarkers are frequently altered in pancreatic adenocarcinoma and precursor lesions

  2018cites this paper
• M 2-Pyruvate Kinase ( M 2-PK ) In 2008

  2018cites this paper
• MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention.

  2017cites this paper
• The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis

  2017cites this paper
• Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment

  2017cites this paper
• High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients

  2017cites this paper
• Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

  2017cites this paper
• HNRNPA2B1 regulates the epithelial–mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway

  2017cites this paper
• Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma

  2017cites this paper
• Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer

  2017cites this paper
• Liquid biopsy in pancreatic cancer

  2017cites this paper
• Innovation of Diagnosis and Treatment for Pancreatic Cancer

  2017cites this paper
• Liquid Biopsy for Early Detection of Pancreatic Cancer

  2017cites this paper
• Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Molecular identification and targeting of colorectal cancer stem cells

  2017influential citation
• ASSOCIAZIONE TRA STATO MUTAZIONALE DI KRAS E PATTERN DI ESPRESSIONE GENETICA NEL CARCINOMA DEL PANCREAS

  2016cites this paper
• Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker

  2016cites this paper
• Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing

  2016cites this paper
• Clinical applications of liquid biopsies in gastrointestinal oncology.

  2016cites this paper
• Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer

  2016cites this paper
• K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis

  2016cites this paper
• Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

  2016cites this paper
• Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer

  2016cites this paper
• Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis

  2016cites this paper
• Study of Clinical Survival and Gene Expression in a Sample of Pancreatic Ductal Adenocarcinoma by Parsimony Phylogenetic Analysis

  2016cites this paper
• Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.

  2016cites this paper
• [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].

  2016cites this paper
• Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis

  2016cites this paper
• Circulating biomarkers to monitor cancer progression and treatment

  2016cites this paper
• Correction: Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing

  2016cites this paper
• Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

  2016cites this paper
• Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.

  2016cites this paper
• Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer

  2016cites this paper
• Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer

  2016cites this paper
• Quel avenir pour l’ADN tumoral circulant ? État des lieux et perspectives dans les cancers colorectaux, pulmonaires non à petites cellules et pancréatiques

  2016cites this paper
• Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer

  2015cites this paper